Artemisinin and CYP2A6 activity in healthy subjects

European Journal of Clinical Pharmacology

Volumn 64, Issue 3, 2008, Pages 283-292

  Asimus, Sara ^a   Hai, Trinh Ngoc ^b   Van Huong, Nguyen ^b   Ashton, Michael ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b National Institute of Malariology Parasitology and Entomology Hanoi   (Viet Nam)

Author keywords

Artemisinin; Coumarin; CYP2A6; Induction; Nicotine

Indexed keywords

ARTEMISININ; BETA GLUCURONIDASE; COTININE; COUMARIN; COUMARIN DERIVATIVE; CYTOCHROME P450 2A6; GLUCURONIDE; NICOTINE GUM; UMBELLIFERONE; UMBELLIFERONE GLUCURONIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASIAN; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DETERMINATION; DRUG EFFECT; DRUG EXCRETION; DRUG GLUCURONIDATION; ENZYME ACTIVITY; ENZYME INDUCTION; GENOTYPE; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MOLECULAR PROBE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEAT PROCEDURE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; URINALYSIS; VIET NAM;

ADULT; ANTIMALARIALS; AREA UNDER CURVE; ARTEMISININS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; COUMARINS; CROSS-OVER STUDIES; ENZYME INDUCTION; HUMANS; MALE; MIXED FUNCTION OXYGENASES; NICOTINE; TANDEM MASS SPECTROMETRY; UMBELLIFERONES; VIETNAM;

EID: 43049179515     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0406-1     Document Type: Article

References (42)

1. Ashton M, Hai TN, Sy ND, Huong DX, Van Huong N, Nieu NT, Cong LD (1998) Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab Dispos 26(1):25-27
2. Ashton M, Nguyen DS, Nguyen VH, Gordi T, Trinh NH, Dinh XH, Nguyen TN, Le DC (1998) Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther 63(4):482-493
3. Asimus S, Gordi T (2007) Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model. Br J Clin Pharmacol 63(6):758-762
4. Asimus S, Elsherbiny D, Hai TN, Jansson B, Huong NV, Petzold MG, Simonsson US, Ashton M (2007) Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam Clin Pharmacol 21(3):307-416
5. Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM (2001) Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos 29(1):30-35
6. Bapiro TE, Sayi J, Hasler JA, Jande M, Rimoy G, Masselle A, Masimirembwa CM (2005) Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. Eur J Clin Pharmacol 61(10):755-761
7. Bogan DP, O'Kennedy R (1996) Simultaneous determination of coumarin, 7-hydroxycoumarin and 7-hydroxycoumarin glucuronide in human serum and plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 686(2):267-273
8. Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, Avery MA, Fromm MF, Eichelbaum M (2005) Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol 67(6):1954-1965
9. Cashman JR, Park SB, Yang ZC, Wrighton SA, Jacob P, 3rd, Benowitz NL (1992) Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N′-oxide. Chem Res Toxicol 5(5):639-646
10. Chen Y, Ferguson SS, Negishi M, Goldstein JA (2003) Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol 64(2):316-324
11. Cholerton S, Idle ME, Vas A, Gonzalez FJ, Idle JR (1992) Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. J Chromatogr 575(2):325-330
12. Cohen AJ (1979) Critical review of the toxicology of coumarin with special reference to interspecies differences in metabolism and hepatotoxic response and their significance to man. Food Cosmet Toxicol 17(3):277-289
13. Gordi T, Nielsen E, Yu Z, Westerlund D, Ashton M (2000) Direct analysis of artemisinin in plasma and saliva using coupled-column high-performance liquid chromatography with a restricted-access material pre-column. J Chromatogr B Biomed Sci Appl 742(1):155-162
14. Green MD, Oturu EM, Tephly TR (1994) Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. Drug Metab Dispos 22(5):799-805
15. Handschin C, Meyer UA (2003) Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev 55(4):649-673
16. Hien TT, White NJ (1993) Qinghaosu. Lancet 341(8845):603-608
17. Ilett KF, Ethell BT, Maggs JL, Davis TM, Batty KT, Burchell B, Binh TQ, Thu le TA, Hung NC, Pirmohamed M, Park BK, Edwards G (2002) Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos 30(9):1005-1012
18. Ingelman-Sundberg M (2004) Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 369(1):89-104
19. Iscan M, Rostami H, Guray T, Pelkonen O, Rautio A (1994) Interindividual variability of coumarin 7-hydroxylation in a Turkish population. Eur J Clin Pharmacol 47(4):315-318
20. Itoh M, Nakajima M, Higashi E, Yoshida R, Nagata K, Yamazoe Y, Yokoi T (2006) Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha. J Pharmacol Exp Ther 319(2):693-702
21. Kharasch ED, Hankins DC, Baxter PJ, Thummel KE (1998) Single-dose disulfiram does not inhibit CYP2A6 activity. Clin Pharmacol Ther 64(1):39-45
22. Kharasch ED, Hankins DC, Taraday JK (2000) Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity. Drug Metab Dispos 28(1):28-33
23. Molander L, Lunell E, Andersson SB, Kuylenstierna F (1996) Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. Clin Pharmacol Ther 59(4):394-400
24. Moran E, O'Kennedy R, Thornes RD (1987) Analysis of coumarin and its urinary metabolites by high-performance liquid chromatography. J Chromatogr 416(1):165-169
25. Nakajima M, Yamagishi S, Yamamoto H, Yamamoto T, Kuroiwa Y, Yokoi T (2000) Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin Pharmacol Ther 67(1):57-69
26. Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, Kwon JT, McLeod HL, Yokoi T (2006) Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 80(3):282-297
27. Oscarson M (2001) Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 29(2):91-95
28. Oscarson M, Gullsten H, Rautio A, Bernal ML, Sinues B, Dahl ML, Stengard JH, Pelkonen O, Raunio H, Ingelman-Sundberg M (1998) Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett 438(3):201-205
29. Pasanen M, Rannala Z, Tooming A, Sotaniemi EA, Pelkonen O, Rautio A (1997) Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. Toxicology 123(3):177-184
30. Peamkrasatam S, Sriwatanakul K, Kiyotani K, Fujieda M, Yamazaki H, Kamataki T, Yoovathaworn K (2006) In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. Drug Metab Pharmacokinetics 21(6):475-484
31. Pelkonen O, Rautio A, Raunio H, Pasanen M (2000) CYP2A6: a human coumarin 7-hydroxylase. Toxicology 144(1-3):139-147
32. Poland RE, Pechnick RN, Cloak CC, Wan YJ, Nuccio I, Lin KM (2000) Effect of cigarette smoking on coumarin metabolism in humans. Nicotine Tob Res 2(4):351-354
33. Rautio A, Kraul H, Kojo A, Salmela E, Pelkonen O (1992) Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics 2(5):227-233
34. Ritschel WA, Brady ME, Tan HS, Hoffmann KA, Yiu IM, Grummich KW (1977) Pharmacokinetics of coumarin and its 7-hydroxy-metabolites upon intravenous and peroral administration of coumarin in man. Eur J Clin Pharmacol 12(6):457-461
35. Shilling WH, Crampton RF, Longland RC (1969) Metabolism of coumarin in man. Nature 221(5181):664-665
36. Simonsson US, Jansson B, Hai TN, Huong DX, Tybring G, Ashton M (2003) Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther 74(1):32-43
37. Simonsson US, Lindell M, Raffalli-Mathieu F, Lannerbro A, Honkakoski P, Lang MA (2006) In vivo and mechanistic evidence of nuclear receptor CAR induction by artemisinin. Eur J Clin Investig 36(9):647-653
38. Sotaniemi EA, Rautio A, Backstrom M, Arvela P, Pelkonen O (1995) CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br J Clin Pharmacol 39(1):71-76
39. Svensson US, Ashton M (1999) Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 48(4):528-535
40. Svensson US, Ashton M, Trinh NH, Bertilsson L, Dinh XH, Nguyen VH, Nguyen TN, Nguyen DS, Lykkesfeldt J, Le DC (1998) Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 64(2):160-167
41. Xu P, Huang SL, Zhu RH, Han XM and Zhou HH (2002) Phenotypic polymorphism of CYP2A6 activity in a Chinese population. Eur J Clin Pharmacol 58(5):333-337
42. Zhang SQ, Hai TN, Ilett KF, Huong DX, Davis TM, Ashton M (2001) Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers. Br J Clin Pharmacol 52(4):377-385